Navigation Links
Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
Date:6/2/2008

CHICAGO and REGENSBURG, Germany, June 2 /PRNewswire/ -- The TGF-beta 2 inhibitor AP 12009, developed by Antisense Pharma, reveals very good safety and tolerability in the systemic treatment of pancreatic carcinoma, malignant melanoma and colorectal carcinoma. AP 12009, administered intravenously, showed a clear proof of concept. Patients with stage IV pancreatic carcinoma, who received AP 12009 for seven days every other week as second or third line therapy, had a median survival time of 29.6 weeks (6.8 months) after start of AP 12009 treatment. One of these patients with several liver metastases even experienced a complete response. Efficacy and safety results of the multicenter Phase I/II study were published today at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA (1).

In the open-label, multicenter, dose-escalation Phase I/II study patients with advanced stage pancreatic carcinoma, malignant melanoma or colorectal carcinoma were included. So far 25 patients have been treated in six cohorts. The first four cohorts received AP 12009 as 7-day on, 7-day off cycles. For this schedule, the maximum tolerated dose (MTD) was reached with two grade III thrombocytopenias as dose-limiting toxicities (DLT). These were self-limiting and required no therapeutic intervention. The third DLT was a grade III rash. Thus, the compound AP 12009 revealed excellent safety and tolerability. Very encouraging case reports were observed. One patient, diagnosed with stage IV malignant melanoma, survived more than 60 weeks after the start of AP 12009 treatment. Another patient with stage IV pancreatic carcinoma and several liver metastases had a complete response and is still alive as of March 2008 148 weeks (34 months) after the start of treatment with AP 12009.

After reaching the MTD with the 7-day on, 7-day off schedule, a second schedule with 4-day on, 10-day off cycles was initiated. Two cohorts with a total of seven patients h
'/>"/>

SOURCE Antisense Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
2. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
3. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
4. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
5. Amikacin Inhale Shows Promising Results in Phase II Study
6. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
7. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
8. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
9. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
10. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
11. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, is ... third international medical cannabis conference taking place at ... France , on October 22, 2014.  The ... stakeholders, such as researchers, health professionals, and patients, ...
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... Conn. , Aug. 21, 2014  Aptuit ... West Lafayette, Indiana , has enhanced ... and characterization of small and large molecules, including ... of the Bruker maXisPlus Q-TOF mass spectrometer. ... Goldman , CEO, Aptuit, said, "The expanded large ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2
... 6 TargeGen, Inc. today announced that,the Company,s ... and the,Company plans to initiate a multi-center clinical ... highly selective JAK2 inhibitor in,January, 2008. Additionally, TargeGen ... will be made at the 2007 ASH Conference,(Atlanta, ...
... Inc. (Nasdaq: BCRX ) today provided an ... Forodesine HCl Data to be Presented at American ... Chair, Dermatology, The University of,Texas M.D. Anderson Cancer ... Phase I/II clinical study of oral forodesine HCl ...
Cached Medicine Technology:TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH 2BioCryst Provides Forodesine HCl Update 2BioCryst Provides Forodesine HCl Update 3BioCryst Provides Forodesine HCl Update 4BioCryst Provides Forodesine HCl Update 5
(Date:8/22/2014)... According to the new research report "Isocyanate ... & Forecast to 2019" defines and segments the ... the market value. The isocyanate material market value ... a significant CAGR from 2014 to 2019. , ... spread through 286 pages and in-depth TOC on ...
(Date:8/22/2014)... the leading pan-European organisation representing medical oncology professionals, ... receiving the Society,s esteemed annual awards. The awards ... and Peter Boyle on the occasion of the ... Carsten Bokemeyer will receive the ESMO Award for ... discovery into real benefit at patient level. 1 ...
(Date:8/22/2014)... 2014 The report "Higher Education ... & Compliance, Campus Technology, Student & Curriculum, Performance ... defines and segments the global Higher Ed market ... forecasting of market sizes. The report also identifies ... opportunities impacting it along with the adoption trends. ...
(Date:8/22/2014)... 2014 A new study finds a wide range ... be related to key environmental exposuresin children with Crohn,s disease ... journal of the Crohn,s & Colitis Foundation of America ... Williams & Wilkins , a part of Wolters Kluwer ... of alterations of DNA in several regions of the genome ...
(Date:8/22/2014)... of Alzheimer,s disease can be slowed and some ... that is found in pomegranate. Also, the ... arthritis and Parkinson,s disease could be reduced, according ... by University of Huddersfield scientist Dr Olumayokun Olajide, ... products. , Now, a new phase of research ...
Breaking Medicine News(10 mins):Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 3Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 4Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:Research underway to create pomegranate drug to stem Alzheimer's and Parkinson's 2
... In a new reflection on the dangers currently gripping humanity, ... to invest in public health and not arms. ... any noble heart, said Castro in his recent article broadcast ... feature, Castro condemned the construction of a "wonderful submarine" in ...
... far better than drinking water, researchers said. ,There ... cups of tea can reduce the risk of heart attacks. ... King's College London, it is a wrong belief that tea ... as it contains antioxidants. It does not dehydrate you, Mirror ...
... a new outbreak of avian flu at three poultry farms ... ,Laboratory tests confirmed the presence of H5N1, a ... three farms in Chak Shehzad, where about 12,000 birds died ... and Livestock Ministry. ,There were no reports of ...
... combination asthma therapy, SYMBICORT leads to significant improvements ... patient-reported satisfaction with asthma treatment, versus its ... ,SYMBICORT is a recently approved, combination therapy indicated ... patients 12 years of age and older. SYMBICORT ...
... comprehensive survey carried out by the World Conservation Union (IUCN) ... threatened with extinction. ,Unless the trend is ... able to meet its self-imposed target of halting biodiversity loss ... that live in Europe and western Russia, some 15 percent ...
... at Arizona State University has used molecular biology tricks to ... with the ones that occurred naturally. ... new proteins in a fraction of the three billion years ... led to some surprisingly new lessons on how to optimize ...
Cached Medicine News:Health News:Combo Therapy may Be Highly Beneficial in Asthma Control 2Health News:One-sixth of Europe's Mammals Face Extinction, Warns Conservation Experts 2
55 DSL's new collection of optical frames has established a strong personality and developed,superficial retro concepts with contemporary styles and strong impacting colours....
... and highly sought-after, the ... collection of sunglasses and ... the very latest men's ... timeless sources of inspiration ...
... Extended Ablation laser enables the physician to provide ... results and no downtime., The new Whisper NG ... an extra long pulse width to achieve "Extended ... over 3-5 days, and occurs simultaneously with the ...
... the art software package designed to assist in ... by a lens manufacturer with years of experience ... is designed to help you run your lab ... the software dictates., ,Designed specifically for integrated retail ...
Medicine Products: